Previous 10 | Next 10 |
Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid. "We look forward to sharing data from our oncology portfolio with the ...
2023-10-13 11:28:03 ET Biopharmaceutical Incyte ( NASDAQ: INCY ) Friday announced that the phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream, Opzelura, in children between ages 2 - 12 with atopic dermatitis met its primary endpoint. Data from the TRu...
- In the TRuE-AD3 trial, children (age ≥2 to <12 years old) with atopic dermatitis (AD) treated with ruxolitinib cream achieved significant efficacy, as defined by the Investigator’s Global Assessment-treatment success (IGA-TS), following eight weeks of treatment - In a...
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA...
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness...
2023-10-11 13:35:35 ET More on Syndax Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript Biggest stock movers today: Arch Resources, Coinbase Global and more Syndax Pharma falls aft...
- Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years - Results were presented in a late-breaking news session at the European Academy of Dermatolo...
Incyte (Nasdaq:INCY) announced today its partnership with actress, singer and songwriter Mandy Moore on Moments of Clarity , an educational initiative highlighting the authentic stories of people living with mild to moderate atopic dermatitis (AD) and their journey to finding relief from ...
- Longer-term use of povorcitinib resulted in further improvement in total body and facial repigmentation - Results were presented in a late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Congress 2023 Incyte (Nasdaq:INCY) today announced new...
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...